Effect of astilbin on experimental diabetic nephropathy in vivo and in vitro

Planta Medica

Volumn 75, Issue 14, 2009, Pages 1470-1475

  Li, Gui Sheng ^a   Jiang, Wang Lin ^a,b   Yue, Xi Dian ^b   Qu, Gui Wu ^b   Tian, Jing Wei ^a   Wu, Juan ^b   Fu, Feng Hua ^a  

^a YANTAI UNIVERSITY   (China)

^b Shandong Engineering Research Center for Nature Drug   (China)

Author keywords

Astilbin 3 0 alpha1rhamnosyl(2R,3R)dihydroquercetin); Connective tissue growth factor; Diabetic nephropathy; Transforming growth factor 1

Indexed keywords

3 0 ALPHA 1 RHAMNOSYL[ 2,3 ]DIHYDROQUERCETIN; ASTILBIN; BENAZEPRIL; CONNECTIVE TISSUE GROWTH FACTOR; GLUCOSE; QUERCETIN DERIVATIVE; SODIUM CHLORIDE; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CELL STIMULATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; KIDNEY FUNCTION; MALE; NONHUMAN; PATHOLOGY; RAT; RENAL PROTECTION; SURVIVAL TIME; WEIGHT GAIN;

ANIMALS; ANTIOXIDANTS; BODY WEIGHT; CELL LINE; CONNECTIVE TISSUE GROWTH FACTOR; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FLAVONOLS; GLUCOSE; HUMANS; KIDNEY; LONGEVITY; MALE; MODELS, ANIMAL; PHYTOTHERAPY; PLANT EXTRACTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RHIZOME; SMILAX; TRANSFORMING GROWTH FACTOR BETA1;

ANIMALIA; SMILAX GLABRA;

EID: 73349118407     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1185802     Document Type: Article

References (26)

1. Ziyadeh F N., Sharma K. Overview: combating diabetic nephropathy. J Am Soc Nephrol 2003 14 1355-1357
2. Abdel W N., Mason R M. Connective tissue growth factor and renal diseases: some answers, more questions. Curr Opin Nephrol Hypertens 2004 13 53-58
3. Van Nieuwenhoven F A., Jensen L J., Flyvbjerg A, Goldschmeding R. Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point? Nephrol Dial Transplant 2005 20 6-10
4. Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am J Pathol 2004 165 2033-2043
5. Kobayashi T, Okada H, Inoue T, Kanno Y, Suzuki H. Tubular expression of connective tissue growth factor correlates with interstitial fibrosis in type 2 diabetic nephropathy. Nephrol Dial Transplant 2006 21 548-549
6. Goldschmeding R, Aten J, Ito Y, Blom I, Rabelink T, Weening J J. Connective tissue growth factor: just another factor in renal fibrosis? Nephrol Dial Transplant 2000 15 296-299
7. Boor P, Sebekovä K, Ostendorf T, Floege J. Treatment targets in renal fibrosis. Nephrol Dial Transplant 2007 22 3391-3407
8. Haraguchi H, Mochida Y, Sakai S, Masuda H, Tamura Y, Mizutani K, Tanaka O, Chou W H. Protection against oxidative damage by dihydroflavonols in Engelhardtia chrysolepis. Biosci Biotechnol Biochem 1996 60 945-948
9. Igarashi K, Uchida Y, Murakami N, Mizutani K, Masuda H. Effect of astilbin in tea processed from leaves of Engelhardtia chrysolepis on the serum and liver lipid concentrations and on the erythrocyte and liver antioxidative enzyme activities of rats. Biosci Biotechnol Biochem 1996 60 513-515
10. Wang J, Zhao Y, Xu Q. Astilbin prevents concanavalin A-induced liver injury by reducing TNF-α production and T lymphocytes adhesion. J Pharm Pharmacol 2004 56 495-502
11. Xu Q, Wu F, Cao J, Chen T, Jiang J, Saiki I, Koda A. Astilbin selectively induces dysfunction of liver-infiltrating cells: novel protection from liver damage. Eur J Pharmacol 1999 377 93-100
12. Yan R, Xu Q. Astilbin selectively facilitates the apoptosis of interleukin-2-dependent phytohemagglutinin-activated Jurkat cells. Pharmacol Res 2001 44 135-139
13. Cai Y, Chen T, Xu Q. Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes. Inflamm Res 2003 52 334-340
14. Fei M J., Wu X F., Xu Q. Astilbin inhibits contact hypersensitivity via negative cytokine regulation distinct form cyclosporin A. J Allergy Clin Immunol 2005 116 1350-1356
15. Chen T, Li J, Cao J, Xu Q, Komatsu K, Namba T. A new flavanone isolated from Rhizoma Smilacis glabrae and the structural requirements of its derivatives for preventing immunological hepatocyte damage. Planta Med 1999 65 559-563
16. Panchapakesan U, Sumual S, Pollock C A., Chen X. PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol 2005 289 1153-1158
17. Thulesen J, Poulsen S S., Jørgensen P E., Nexø E. Adrenergic blockade in diabetic and uninephrectomized rats: effects on renal size and on renal and urinary contents of epidermal growth factor. Nephron 1999 81 172-182
18. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998 339 1448-1456
19. Mauer S M. Structural-functional correlations of DN. Kidney Int 1994 45 612-622
20. Wolf G, Ziyadeh F N. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999 56 393-405 (Pubitemid 29353136)
21. Paueksakon P, Revelo M P., Ma L J., Marcantoni C, Fogo A B. Microangiopathic injury and augmented PAI1 in human diabetic nephropathy. Kidney Int 2002 61 2142-2148
22. Lee H B., Ha H. Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology 2005 10 S11-S13
23. Bottinger E P., Letterio J J., Roberts A B. Biology of TGF-β1 in knockout and transgenic mouse models. Kidney Int 1997 51 1355-1360
24. Schull M M., Ormsby I, Kier A B. Targeted disruption of the mouse TGF-1 gene results in multifocal inflammatory disease. Nature 1992 359 693-699
25. Rossing P. Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus. Diabet Med 1998 15 900-919 (Pubitemid 28500243)
26. Lewis E J., Hunsicker L G., Bain R P., Rohde R D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993 329 1456-1462